| ||||||||||||||||
Home Product Information General Information
|
Folic Acid $17.95 for 500 Tabs 800 mcg | Order
| Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Division of Cardiology, Swiss Cardiovascular Center Bern, University Hospital, Switzerland. g.schnyder@lycos.com CONTEXT: Plasma homocysteine level has been recognized as an important cardiovascular risk factor that predicts adverse cardiac events in patients with established coronary atherosclerosis and influences restenosis rate after percutaneous (surgical) coronary intervention. OBJECTIVE: To evaluate the effect of homocysteine-lowering therapy on clinical outcome after percutaneous coronary intervention. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind placebo-controlled trial involving 553 patients referred to the University Hospital in Bern, Switzerland, from May 1998 to April 1999 and enrolled after successful angioplasty of at least 1 significant coronary stenosis (> or = 50%). INTERVENTION: Participants were randomly assigned to receive a combination of folic acid (1 mg/d), vitamin B(12) (cyanocobalamin, 400 micro g/d), and vitamin B(6) (pyridoxine hydrochloride, 10 mg/d) (n = 272) or placebo (n = 281) for 6 months. MAIN OUTCOME MEASURE: Composite end point of major adverse events defined as death, nonfatal myocardial infarction, and need for repeat revascularization, evaluated at 6 months and 1 year. RESULTS: After a mean (SD) follow-up of 11 (3) months, the composite end point was significantly lower at 1 year in patients treated with homocysteine-lowering therapy (15.4% vs 22.8%; relative risk [RR], 0.68; 95% confidence interval [CI], 0.48-0.96; P =.03), primarily due to a reduced rate of target lesion revascularization (9.9% vs 16.0%; RR, 0.62; 95% CI, 0.40-0.97; P =.03). A nonsignificant trend was seen toward fewer deaths (1.5% vs 2.8%; RR, 0.54; 95% CI, 0.16-1.70; P =.27) and nonfatal myocardial infarctions (2.6% vs 4.3%; RR, 0.60; 95% CI, 0.24-1.51; P =.27) with homocysteine-lowering therapy. These findings remained unchanged after adjustment for potential confounders. CONCLUSION: Homocysteine-lowering therapy with
folic acid, vitamin B(12), and vitamin B(6) significantly decreases the
incidence of major adverse events after percutaneous (surgical) coronary intervention.
PMID: 12190367 [PubMed - indexed for MEDLINE]
Folic Acid, along with vitamin B-12, is required for the synthesis of DNA, the principal genetic material in the body. It helps prevent neural tube defects in developing embryos, making it an important nutritional supplement for women who are, or intend to become, pregnant. |
|
|
© 1998-2008 by The Hormone Shop, LLC.
Web Masters: Check out our New
Affiliate Program Paying up to 20% !!! Disclaimer: The Hormone Shop LLC assumes no liability, whether under a theory of contract, tort, negligence, product liability or otherwise. In no event shall The Hormone Shop LLC be liable for any direct or indirect, consequential, incidental, special, punitive or exemplary damages, or for any loss incurred due to results or comments that are reported or the use of collection materials that are supplied, or any prescriptions regardless of whether The Hormone Shop LLC knew or should have known of the possibility of such damages. Furthermore, in no event shall The Hormone Shop LLC's total cumulative liability exceed The Hormone Shop LLC's net profit on any specific product, sample or consultation giving rise to the liability. The Hormone Shop LLC specifically assumes no liability incurred by any 3rd party associate and if you are reading this web site in a language other that English it has been machine translated by SYSTRAN who strives to achieve the highest possible accuracy, however no automated translation is perfect nor is it intended to replace human translators. Users should note that the quality of the source text significantly affects the translations and The Hormone Shop LLC assumes no liability for incorrect or misleading translations. The questions and comments appearing in the "Discussion Group Forum" are strictly from unknown or unidentified sources and the reader/participant should be aware that credentials from any source are completely lacking and should be questioned. The Hormone Shop LLC specifically assumes no liability for any comment or advice appearing in the "Discussion Forum".
Notice: This information on anti-aging products is provided for educational and nutritional purposes. Any medical procedures, dietary changes or the use of dietary supplements discussed herein should only be undertaken on the advice of a qualified medical doctor. Although listed and sold as dietary supplements these are not innocuous, inert substances; rather they can and do affect vital systems within the human body and it is for this reason that you are urged to find a medical doctor who will work with you in monitoring and maintaining your well being. A to Z Treasures of Yesterday http://www.drugsfromindia.net/fsh.htm http://www.drugsfromindia.net/menshealth.htm Laboratory
|
